Unigene acquires exclusive worldwide rights to oral PTH program from GSK

[News]

Unigene Laboratories, Inc. today announced that the Company terminated its amended and restated exclusive worldwide license agreement and related development services and clinical supply agreement with GlaxoSmithKline (GSK) pertaining to an oral formulation of a recombinantly produced parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women.

More... (http://www.news-medical.net/news/20111205/Unigene-acquires-exclusive-worldwide-rights-to-oral-PTH-program-from-GSK.aspx)